National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting, 22503 [2019-10218]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 96 / Friday, May 17, 2019 / Notices
Rockledge Drive, Room 1458, MSC 6902,
National Institutes Of Health, Bethesda, MD
20892, 301–443–9737, bautista@
mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.niaaa.nih.gov/about-niaaa/our-work/
advisory-council where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Dated: May 13, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–10219 Filed 5–16–19; 8:45 am]
BILLING CODE 4140–01–P
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: May 13, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–10218 Filed 5–16–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: RP2 AAV Vectors for
Treating X-Linked Retinitis Pigmentosa
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
National Institutes of Health
jbell on DSK3GLQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; RFA AA19–004 Specialized
Alcohol Research Centers.
Date: August 13–14, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 6700 B Rockledge Drive,
Conference Rooms B & C, Bethesda, MD
20817.
Contact Person: Beata Buzas, Ph.D.,
Scientific Review Officer, National Institute
on Alcohol Abuse and Alcoholism, National
Institutes of Health, 6700 B Rockledge Drive,
Room 2116, Rockville, MD 20852, 301–443–
0800, bbuzas@mail.nih.gov.
17:05 May 16, 2019
Notice.
The National Eye Institute, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
U.S. and foreign Patents and Patent
Applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice to IVERIC bio, Inc. located in
New York, NY.
DATES: Only written comments and/or
applications for a license which are
received by the National Eye Institute
c/o National Cancer Institute’s
Technology Transfer Center on or before
June 3, 2019 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Alan Hubbs, Ph.D., Senior
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, Rm. 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702, Telephone: (240)–276–5530,
Email: hubbsa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement:
SUMMARY:
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
VerDate Sep<11>2014
National Institutes of Health,
HHS.
Jkt 247001
Intellectually Property
1. U.S. Provisional Patent Application
No. 62/131,661, filed March 11, 2015
[HHS Reference No. E–050–2015/0–US–
01];
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
22503
2. PCT Patent Application No. PCT/
US2016/022072 filed March 11, 2016
[HHS Reference No. E–050–2015–0–
PCT–03];
3. Australian Patent Application No.
AU2016228751A, filed on March 11,
2016 [HHS Reference No. E–050–2015–
0–AU–04];
4. Canadian Patent Application No.
CA2979229A, filed on March 11, 2016
[HHS Reference No. E–050–2015–0–
CA–05];
5. European Patent Application No.
EP16762623.3A, filed on March 11,
2016 [HHS Reference No. E–050–2015–
0–EP–06];
6. Japanese Patent Application No.
JP2017547425A, filed on March 11,
2016 [HHS Reference No. E–050–2015–
0–JP–07];
7. United States Patent Application
No. US15/556,746, filed on March 11,
2016 [HHS Reference No. E–050–2015–
0–US–08].
With respect to persons who have an
obligation to assign their right, title and
interest to the Government of the United
States of America, the patent rights in
these inventions have been assigned to
the Government of the United States of
America. The prospective exclusive
license territory may be world-wide,
and the field of use may be limited to
the use of Licensed Patent Rights for the
following: ‘‘Human therapeutics for
treating x-linked retinitis pigmentosa:
The license will also be limited by
licensed products covered by patent
rights that pertain to AAV-mediated
gene therapy delivering an RP2
transgene.’’
This technology discloses adenoassociated virus (AAV) vectors
comprising nucleotide sequences
encoding RPGR–ORF15 or RP2 and
related pharmaceutical compositions. It
also discloses methods of treating or
preventing x-linked retinitis
pigmentosa, increasing photoreceptor
number in the retina of a mammal, and
increasing visual acuity of a mammal
using the vectors and pharmaceutical
compositions.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National Eye
Institute receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
E:\FR\FM\17MYN1.SGM
17MYN1
]]>Agencies
[Federal Register Volume 84, Number 96 (Friday, May 17, 2019)]
[Notices]
[Page 22503]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-10218]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Alcohol Abuse and
Alcoholism Special Emphasis Panel; RFA AA19-004 Specialized Alcohol
Research Centers.
Date: August 13-14, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on
Alcohol Abuse and Alcoholism, 6700 B Rockledge Drive, Conference
Rooms B & C, Bethesda, MD 20817.
Contact Person: Beata Buzas, Ph.D., Scientific Review Officer,
National Institute on Alcohol Abuse and Alcoholism, National
Institutes of Health, 6700 B Rockledge Drive, Room 2116, Rockville,
MD 20852, 301-443-0800, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.271,
Alcohol Research Career Development Awards for Scientists and
Clinicians; 93.272, Alcohol National Research Service Awards for
Research Training; 93.273, Alcohol Research Programs; 93.891,
Alcohol Research Center Grants; 93.701, ARRA Related Biomedical
Research and Research Support Awards, National Institutes of Health,
HHS)
Dated: May 13, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-10218 Filed 5-16-19; 8:45 am]
BILLING CODE 4140-01-P
